A new paradigm for the development of anticancer agents from natural products

Balanehru Subramanian, Alexander Nakeff, Karen Tenney, Phillip Crews, Leslie Gunatilaka, Fred Valeriote

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

A novel pharmacology paradigm has been developed which quickly and efficiently moves prospective anticancer drugs from the discovery phase through pharmacology testing and into therapeutic trial assessment. Following discovery, the drug is first assessed in a clonogenic assay which determines the cytotoxic effect of different concentrations of the drug at 3 different exposure durations: 2h, 24h and continuous (168 h). Second, pharmacokinetic information is obtained in both plasma and tumor for the drug administered at the maximum tolerated dose given intravenously. The first study defines the time-concentration profile required to obtain a specific cell survival for the tumor cells; the second study determines the concentration-time profile that can be obtained in both plasma and tumor at the maximum tolerated dose of the drug. The integration of this information determines whether a successful therapeutic trial is possible. Only when a drug shows therapeutic efficacy is a proteomics-based mechanism of action study initiated. Two drugs have been assessed in this paradigm: salicortin and fascaplysin A.

Original languageEnglish (US)
Pages (from-to)195-204
Number of pages10
JournalJournal of Experimental Therapeutics and Oncology
Volume5
Issue number3
StatePublished - 2006

Fingerprint

Biological Products
Antineoplastic Agents
Pharmaceutical Preparations
Maximum Tolerated Dose
Pharmacology
Neoplasms
Drug Discovery
Proteomics
Cell Survival
Therapeutics
Pharmacokinetics

Keywords

  • Anticancer
  • Drug development
  • Fascaplysin A
  • Natural products
  • Salicortin

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Subramanian, B., Nakeff, A., Tenney, K., Crews, P., Gunatilaka, L., & Valeriote, F. (2006). A new paradigm for the development of anticancer agents from natural products. Journal of Experimental Therapeutics and Oncology, 5(3), 195-204.

A new paradigm for the development of anticancer agents from natural products. / Subramanian, Balanehru; Nakeff, Alexander; Tenney, Karen; Crews, Phillip; Gunatilaka, Leslie; Valeriote, Fred.

In: Journal of Experimental Therapeutics and Oncology, Vol. 5, No. 3, 2006, p. 195-204.

Research output: Contribution to journalArticle

Subramanian, B, Nakeff, A, Tenney, K, Crews, P, Gunatilaka, L & Valeriote, F 2006, 'A new paradigm for the development of anticancer agents from natural products', Journal of Experimental Therapeutics and Oncology, vol. 5, no. 3, pp. 195-204.
Subramanian, Balanehru ; Nakeff, Alexander ; Tenney, Karen ; Crews, Phillip ; Gunatilaka, Leslie ; Valeriote, Fred. / A new paradigm for the development of anticancer agents from natural products. In: Journal of Experimental Therapeutics and Oncology. 2006 ; Vol. 5, No. 3. pp. 195-204.
@article{c2167c7cf12b49969571788d81edb4ed,
title = "A new paradigm for the development of anticancer agents from natural products",
abstract = "A novel pharmacology paradigm has been developed which quickly and efficiently moves prospective anticancer drugs from the discovery phase through pharmacology testing and into therapeutic trial assessment. Following discovery, the drug is first assessed in a clonogenic assay which determines the cytotoxic effect of different concentrations of the drug at 3 different exposure durations: 2h, 24h and continuous (168 h). Second, pharmacokinetic information is obtained in both plasma and tumor for the drug administered at the maximum tolerated dose given intravenously. The first study defines the time-concentration profile required to obtain a specific cell survival for the tumor cells; the second study determines the concentration-time profile that can be obtained in both plasma and tumor at the maximum tolerated dose of the drug. The integration of this information determines whether a successful therapeutic trial is possible. Only when a drug shows therapeutic efficacy is a proteomics-based mechanism of action study initiated. Two drugs have been assessed in this paradigm: salicortin and fascaplysin A.",
keywords = "Anticancer, Drug development, Fascaplysin A, Natural products, Salicortin",
author = "Balanehru Subramanian and Alexander Nakeff and Karen Tenney and Phillip Crews and Leslie Gunatilaka and Fred Valeriote",
year = "2006",
language = "English (US)",
volume = "5",
pages = "195--204",
journal = "Journal of Experimental Therapeutics and Oncology",
issn = "1359-4117",
publisher = "Old City Publishing",
number = "3",

}

TY - JOUR

T1 - A new paradigm for the development of anticancer agents from natural products

AU - Subramanian, Balanehru

AU - Nakeff, Alexander

AU - Tenney, Karen

AU - Crews, Phillip

AU - Gunatilaka, Leslie

AU - Valeriote, Fred

PY - 2006

Y1 - 2006

N2 - A novel pharmacology paradigm has been developed which quickly and efficiently moves prospective anticancer drugs from the discovery phase through pharmacology testing and into therapeutic trial assessment. Following discovery, the drug is first assessed in a clonogenic assay which determines the cytotoxic effect of different concentrations of the drug at 3 different exposure durations: 2h, 24h and continuous (168 h). Second, pharmacokinetic information is obtained in both plasma and tumor for the drug administered at the maximum tolerated dose given intravenously. The first study defines the time-concentration profile required to obtain a specific cell survival for the tumor cells; the second study determines the concentration-time profile that can be obtained in both plasma and tumor at the maximum tolerated dose of the drug. The integration of this information determines whether a successful therapeutic trial is possible. Only when a drug shows therapeutic efficacy is a proteomics-based mechanism of action study initiated. Two drugs have been assessed in this paradigm: salicortin and fascaplysin A.

AB - A novel pharmacology paradigm has been developed which quickly and efficiently moves prospective anticancer drugs from the discovery phase through pharmacology testing and into therapeutic trial assessment. Following discovery, the drug is first assessed in a clonogenic assay which determines the cytotoxic effect of different concentrations of the drug at 3 different exposure durations: 2h, 24h and continuous (168 h). Second, pharmacokinetic information is obtained in both plasma and tumor for the drug administered at the maximum tolerated dose given intravenously. The first study defines the time-concentration profile required to obtain a specific cell survival for the tumor cells; the second study determines the concentration-time profile that can be obtained in both plasma and tumor at the maximum tolerated dose of the drug. The integration of this information determines whether a successful therapeutic trial is possible. Only when a drug shows therapeutic efficacy is a proteomics-based mechanism of action study initiated. Two drugs have been assessed in this paradigm: salicortin and fascaplysin A.

KW - Anticancer

KW - Drug development

KW - Fascaplysin A

KW - Natural products

KW - Salicortin

UR - http://www.scopus.com/inward/record.url?scp=33646678195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646678195&partnerID=8YFLogxK

M3 - Article

C2 - 16528970

AN - SCOPUS:33646678195

VL - 5

SP - 195

EP - 204

JO - Journal of Experimental Therapeutics and Oncology

JF - Journal of Experimental Therapeutics and Oncology

SN - 1359-4117

IS - 3

ER -